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A b s t r a c t
Introduction: Well-organized, effective secondary prevention of coronary artery disease (CAD) has a potential to improve the 
patients’ prognosis following myocardial revascularization procedures.
Aim: To evaluate overtime changes in the implementation of the ESC guidelines for secondary prevention by assessing control 
of the main risk factors and the rate of cardioprotective drug use in patients following myocardial revascularization procedures. 
Material and methods: Patients aged < 81 years who had been hospitalized for a myocardial revascularization procedure in five 
hospitals serving Krakow and surrounding districts were recruited and interviewed 6–18 months following discharge. Their personal 
medical history, medication use and control of the main cardiovascular risk factors were evaluated using a standard questionnaire 
in 2006–2007, 2011–2013, and 2016–2017. The same five hospitals took part in surveys on each occasion. 
Results: We examined 260 patients in 2006–2007, 200 in 2011–2013 and 190 in 2016–2017. We noted a significant difference 
in the management of surveys participants: 62% underwent percutaneous coronary intervention (PCI) and 38% coronary artery 
coronary artery bypass grafting (CABG) in 2006–2007 whereas the corresponding proportions in 2016–2017 were 90% and 10%. 
The proportion of patients who did not achieve target blood pressure (according to ESC guidelines valid at the time of each survey) 
in 2006–2007, 2011–2013 and 2016–2017 was 53.5%, 52.3%, and 38.9%, respectively, the proportion of those who did not achieve 
the LDL cholesterol target (according to ESC guidelines valid at the time of each survey) was 36.3%, 64.0%, and 61.7%, respectively, 
and the proportion of those with high fasting glucose was 12.6%, 14.6%, and 19.7%, respectively. The proportion of smokers was 
16.2%, 19.5%, and 16.8%, whereas 30.5%, 28.6% and 40.5% of patients were obese in 2006–2007, 2011–2013 and 2016–2017, 
respectively. The proportion of patients taking antiplatelets (91.8% vs. 92.0% vs. 96.3%), β-blockers (90.3% vs. 87.5% vs. 92.6%), and 
lipid-lowering drugs (88.7% vs. 91.0% vs. 93.7%) did not change significantly.
Conclusions: The analysis of three multicenter surveys provides evidence of the considerable potential for a further reduction in 
cardiovascular risk in patients following elective myocardial revascularization in Poland.
Key words: coronary artery disease, risk factors, secondary prevention, coronary artery bypass grafting, percutaneous coronary 
intervention.
S u m m a r y
The aim of this study was to evaluate the implementation of the guidelines for secondary prevention of coronary artery 
disease in patients following non-emergency coronary artery bypass grafting or percutaneous coronary intervention. Control 
of risk factors and cardioprotective drug use was similar in patients who had undergone percutaneous or surgical revascu-
larization. The analysis of three multicenter surveys provides evidence of a persistent potential for further improvement in 
cardiovascular risk in revascularized patients.
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present analysis. A fasting venous blood sample was tak-
en to measure plasma lipid and glucose levels. Glycated 
hemoglobin (HbA1c) was not measured in 2006–2007 and 
was only recorded in half of the participants in the survey 
in 2011–2013. The blood samples were analyzed in the 
central laboratory. The same laboratory was used in each 
survey. For the present report, we used the results of anal-
yses performed no later than 12 h after blood collection.
We analyzed the proportions of patients with risk 
factors not at recommended goals: smoking, a  fasting 
glucose level ≥ 7.0 mmol/l, BMI ≥ 25 kg/m2, waist cir-
cumference ≥ 88 cm in women and ≥ 102 cm in men. In 
the case of blood pressure and low-density lipoprotein 
(LDL) cholesterol two approaches were adopted. First, we 
analyzed the proportions of patients achieving goals rec-
ommended at the time of each survey. Second, we also 
analyzed the proportions of patients with blood pressure 
and LDL cholesterol levels above the goal values recom-
mended at the time of the final survey. 
The secondary prevention coefficient was calculated 
in the following way: one point was given for each con-
trolled risk factor (non-smoking, blood pressure at goal, 
LDL cholesterol at goal, glucose < 7.0 mmol/l, BMI < 25 
kg/m2) during the follow-up examination. The goal val-
ues for blood pressure and LDL cholesterol were based 
on the ESC guidelines, which were valid at the time each 
survey was conducted. Additionally, one point was given 
for taking an antiplatelet agent and an ACE inhibitor or 
an angiotensin II receptor antagonist. Thus, a patient’s 
secondary prevention coefficient could vary from 0 to 7.
The surveys protocols were approved by the institu-
tional Bioethics Committee. All the patients signed an 
informed consent form. 
Statistical analysis
Categorical variables were reported as percentages 
and continuous variables as means ± standard deviation. 
The Pearson χ2 test was applied to all the categorical 
variables. Normally distributed continuous variables were 
compared using Student’s t test or analysis of variance. 
Variables without normal distributions were evaluated 
using the Mann-Whitney U  test or the Kruskal-Wallis 
analysis of variance. Generalized linear models as imple-
mented in the Statistica 13 software (TIBCO Software, 
USA) were used to compare proportions after adjust-
ment for age, sex, procedure, duration of education, pro-
fessional activity, and period of time from discharge to 
the examination. Factors independently related to the 
secondary prevention coefficient were evaluated using 
multivariable regression analysis. A two-tailed p-value of 
less than 0.05 was regarded as statistically significant.
Results
We examined 260 patients in 2006-2007 (participa-
tion rate 84.1%), 200 in 2011–2013 (60.2%) and 190 pa-
Introduction
Cardiovascular diseases are a leading cause of mor-
tality in developed countries [1]. Despite advances in the 
pharmacological and invasive treatment of coronary ar-
tery disease (CAD) in recent years the risk of recurrent 
cardiovascular events in patients with CAD remains high 
[2, 3]. Patients who have undergone an elective myocar-
dial revascularization procedure also constitute a  very 
high cardiovascular risk group and have the most to gain 
from secondary prevention [4]. One of the most import-
ant factors increasing the risk of mortality in patients 
with established CAD is still unsatisfactory secondary 
prevention including lifestyle changes, control of risk fac-
tors and pharmacotherapy [4–8].
Aim
The aim of the present analysis was to evaluate tem-
poral changes in the implementation of European Society 
of Cardiology (ESC) guidelines for secondary prevention 
by assessing control of the main risk factors and the rate 
of cardioprotective drug use in patients following myo-
cardial revascularization procedures.
Material and methods
We analyzed the data of participants from three sur-
veys appraising secondary prevention in patients with 
established CAD in 2006–2007, 2011–2013, and 2016–
2017 [9–11]. The same five hospitals providing cardiolog-
ical care in the city and surrounding districts participated 
in each survey. The methods used in surveys had been 
published previously and were similar each time [9–11]. 
Briefly, patients aged < 81 years and hospitalized for an 
acute coronary syndrome or a  myocardial revascular-
ization procedure were recruited and interviewed 6–18 
months after discharge from hospital. The inclusion cri-
teria for the present analysis were elective percutaneous 
coronary intervention (PCI) or scheduling for coronary ar-
tery bypass grafting (CABG). A patient’s personal medical 
history, lifestyle and medications used were evaluated 
using a standard questionnaire. Diabetes status was de-
termined based on the diagnosis found in the discharge 
letter. Smoking status was verified by assessing the con-
centration of breath carbon monoxide using a Smokerlyz-
er (Bedfont Scientific). Height and weight were measured 
in a standing position without shoes and heavy outwear 
using standard scales with a vertical ruler (SECA). Body 
mass index (BMI) was calculated according to the fol-
lowing formula: BMI = weight [kg]/(height [m])2. Waist 
circumference was measured using a  metal tape mea-
sure placed horizontally in the mid-axillary line, midway 
between the lowest rim of the rib cage and the tip of the 
hip bone with the patient in a standing position. Blood 
pressure was measured twice, on the right arm in a sit-
ting position after at least 5 min of rest using an auto-
matic device. The mean of two readings was used for the 
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tients in 2016–2017 (72.8%). The characteristics of the 
studied groups are presented in Table I. Participants of 
the third (2016-2017) survey were older, better educated 
and more likely to be employed compared to the partici-
pants of the first (2006–2007) and second (2011–2013) 
surveys. There was no significant difference in gender 
distribution between the surveys. A  statistically signifi-
cant decrease in the proportion of post-CABG patients 
was observed in each successive study. 
Mean diastolic blood pressure and LDL cholesterol 
levels decreased over time, while no significant differ-
ences were observed in systolic blood pressure, glucose 
levels, HbA1c levels, or CO in exhaled air between the sur-
veys (Table II). Differences in the proportion of patients 
who did not reach treatment goals 6–18 months after 
discharge from hospital adjusted for a number of co-fac-
tors are shown in Table III. The was no significant differ-
ence in proportion of patients with fasting glucose ≥ 7.0 
mmol/l among those with diagnosed diabetes: 44.3% in 
2006–2007 vs. 44.9% in 2016–2017 (p = NS). 
After multivariable adjustments we did not observe 
any statistically significant difference in the use of anti-
platelets (91.8% in 2006–2007 vs. 96.3% in 2016–2017), 
β-blockers (90.3% in 2006–2007 vs. 92.6% in 2016–
2017), or lipid-lowering drugs (88.7% in 2006–2007 vs. 
93.7% in 2016–2017) 6–18 months after discharge from 
hospital (Table IV). In the same time, the proportion of 
patients reporting the use of calcium antagonists, diuret-
ics, antidiabetics agents and anticoagulants increased 
significantly.
The mean secondary prevention coefficient was 4.79 
±1.07 (median value: 5; first quartile: 4; third quartile 6) 
in 2006–2007, 4.42 ±1.14 (median value: 4; first quartile: 
4; third quartile 5) in 2011–2013 (p < 0.001 vs. 2006–
2007), and 4.67 ±1.04 (median value: 5; first quartile: 4; 
third quartile 5) in 2016–2017 (p = 0.26 vs. 2006–2007). 
Its value was equal to 7 in just 2.4% of patients in 2006–
2007, 1.7% in 2011–2013, and 1.6% in 2016–2017, while 
25.4% of survey participants in 2006–2007, 18.0% in 
2011–2013, and 22.3% in 2016–2017 had a secondary 
prevention coefficient of at least 6 (p = 0.20). Figure 1 
presents the mean secondary prevention coefficient val-
ues according to myocardial revascularization procedure 
and survey. Age, education and participation in second 
survey as compared to the first survey were related to 
the value of the secondary prevention coefficient in mul-
tivariable analysis (Table V). 
Discussion
Results of the EUROASPIRE surveys demonstrated the 
potential for further improvement in cardiovascular risk 
in patients with CAD [6, 8]. Lifestyle changes, control of 
risk factors and appropriate pharmacotherapy are major 
factors reducing the risk of cardiovascular events in CAD 
patients. The goal of elective myocardial revasculariza-
tion is to alleviate symptoms in patients with angina and 
improve prognosis [12–14]. Although recently published 
results of the ISCHEMIA trial showed no significant influ-
ence of myocardial revascularization on cardiovascular 
event risk in patients with stable CAD, it showed a  sig-
nificant influence on angina, quality of life and physical 
performance [15, 16]. Several previous studies have also 
shown that myocardial revascularization is not only more 
effective in reducing angina and the need for antianginal 
drugs, but also improves physical performance and quali-
ty of life compared to the conservative treatment strategy 
both in a short- and long-term follow-up [17, 18]. Howev-
er, the failure to properly implement lifestyle changes may 









Age [years] 62.6 ±8.9 64.2 ±7.9 67.0 ±7.3*† 64.4 ±8.4
Sex (%):
Men 77.3 77.5 80.5 78.3
Women 22.7 22.5 19.5 21.7
Duration of education [years] 11.8 ±3.3 11.6 ±3.0 13.0 ±3.3*† 12.1 ±3.3
Employed (%) 37.4 24.0* 30.0 31.1
Diabetes (%) 23.5 36.0* 36.3* 31.1
Index event (%):
PCI 62.3 70.5 90.0*† 72.9
CABG 37.7 29.5 10.0*† 27.1
Time from discharge from the hospital  
to the follow-up examination [years]
1.18 ±0.40 1.05 ±0.21* 0.82 ±0.29*† 1.03 ±0.38
CABG – coronary artery bypass grafting, PCI – percutaneous coronary intervention. *p < 0.05 vs. 2006–2007, †p < 0.05 vs. 2011–2013.
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contradict the benefits arising from the rapid develop-
ment of pharmacological and invasive treatment of cor-
onary artery disease observed in recent years [8, 19, 20]. 
The present analysis shows no significant improve-
ment in the control of the main CAD risk factors and no 
significant change in the proportion of patients reporting 
the use of antiplatelets, β-blockers, and lipid-lowering 
drugs 6–18 months after discharge from the hospital. 
Importantly, when we used the LDL cholesterol goal as 
recommended in the ESC guidelines at the time of each 
survey, the proportion of patients reaching their LDL 
cholesterol goal decreased significantly [21–23]. This 
finding could be explained by the insufficient increase in 
doses of lipid-lowering drugs. In addition, an increased 
waist circumference could also play a  role. In addition, 
the increase in BMI and waist (especially prominent 
among females) could also influence the effectiveness 
of treatment of hypertension and diabetes. Furthermore, 
the comparison of the secondary prevention coefficient 
across the surveys likewise failed to provide any evidence 
of an improvement in the quality of medical care in the 
field of secondary prevention of CAD. Moreover, the mul-
tivariable analysis of the secondary prevention coeffi-
cient suggests even a decreased coefficient in the second 
as compared to first survey. Taking all these factors into 
consideration, the present results suggest that there is 
still a considerable potential for reducing cardiovascular 
risk in patients after myocardial revascularization. 
Traditional cardiac rehabilitation programs are less 
effective for patients with a lower level of education and 
tend to be less efficient in patients after non-emergency 
myocardial revascularization compared to subjects with 
acute coronary syndromes [24, 25]. Indeed, several re-
cent initiatives have aimed at improving cardiovascular 
risk through education-based secondary prevention pro-
grams [26–28]. 
The present analysis presents a considerable change 
in the characteristics of patients undergoing myocardi-
al revascularization, including the difference in age and 
education, as well as a shift in the management of cor-
onary patients. Indeed, although we used the same in-
clusion criteria 62% of analyzed patients underwent PCI 
and 38% CABG in 2006–2007 whereas the correspond-
ing proportions of patients undergoing PCI and CABG in 
2016–2017 were 90% and 10%. 
In summary, our results suggest decreasing mean 
LDL cholesterol and blood pressure, but increasing mean 
fasting glucose and waist circumference in patients with 
established CAD. Among participants of the last survey 
17% were smokers, 39% had high blood pressure, 62% 
high LDL cholesterol, 20% high fasting glucose, 41% were 
obese and 57% had central obesity.
Our analysis has some limitations. Firstly, the partic-
ipants were limited to those who had experienced an 
elective myocardial revascularization procedure. As a con-
sequence, our results should not be directly applied to oth-
er CAD patients. Secondly, the participants of the surveys 
lived in a defined geographical area. Although the applica-
bility of our results to other regions is uncertain, the ob-
served trends accord with changes over time in the gener-









CO in exhaled air [ppm] 4.1 ±4.9 3.9 ±4.5 3.3 ±4.1 3.8 ±4.5
Blood pressure [mm Hg]:
Systolic 137.5 ±21.0 135.1 ±22.4 133.9 ±17.9 135.7 ±20.6
Diastolic 84.7 ±10.6 79.7 ±12.3* 79.5 ±10.6* 81.6 ±11.4
Total cholesterol [mmol/l] 4.41 ±1.04 4.51 ±1.15 4.04 ±1.03*† 4.33 ±1.08
LDL cholesterol [mmol/l] 2.38 ±0.89 2.48 ±1.00 2.08 ±0.84*† 2.32 ±0.92
HDL [mmol/l] 1.34 ±0.36 1.30 ±0.37 1.27 ±0.39 1.31 ±0.38
Triglycerides [mmol/l] 1.53 ±1.06 1.61 ±1.13 1.48 ±0.84 1.54 ±1.02
Glucose [mmol/l] 5.85 ±1.70 6.16 ±1.89* 6.23 ±1.60* 6.05 ±1.74
HbA
1C
‡ (%) – 6.19 ±0.88 6.13 ±0.80 6.15 ±0.83
Body mass index [kg/m2] 28.2 ±4.1 28.2 ±4.0 28.9 ±4.1 28.4 ±4.1
Waist circumference [cm]:
Men 100.0 ±10.4 97.9 ±10.0 103.0 ±11.0*† 100.3 ±10.6
Women 91.8 ±11.3 95.3 ±12.6 97.1 ±10.6* 93.9 ±11.8
HDL – high-density lipoprotein, LDL – low-density lipoprotein. ‡Available for 105 patients in 2011–2013 and 187 patients in 2016–2017, not measured in 2006–2007. 
*p < 0.05 vs. 2006–2007, †p < 0.05 vs. 2011–2013.
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al population in Poland as well as in patients with CAD in 
other European countries [6, 29]. Thirdly, we could not an-
alyze the dosages of prescribed drugs and lifestyle habits 
of the surveys participants, which could even increase the 
impact of the present results. Further studies should aim 
at estimating individual drug doses and lifestyle factors. 
Conclusions
The analysis of three multicenter surveys provides 
evidence of a considerable potential for further improve-
ment in cardiovascular risk in revascularized patients. 
Moreover, our data suggest no consistent improvement 
in the effectiveness of secondary prevention efforts. 
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Figure 1. Mean values of the secondary preven-
tion coefficient to myocardial revascularization 
procedure and survey
Table V. Factors related to the value of the se-
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PCI (PCI – 1, CABG – 0) 0.04 ±0.04 0.40
Time from the index hospitalization 
to examination [years]
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CABG – coronary artery bypass grafting, PCI – percutaneous coronary interven-
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